CN112368376A - 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途 - Google Patents

溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途 Download PDF

Info

Publication number
CN112368376A
CN112368376A CN201980036007.XA CN201980036007A CN112368376A CN 112368376 A CN112368376 A CN 112368376A CN 201980036007 A CN201980036007 A CN 201980036007A CN 112368376 A CN112368376 A CN 112368376A
Authority
CN
China
Prior art keywords
seq
lysin
polypeptide
activity
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980036007.XA
Other languages
English (en)
Chinese (zh)
Inventor
R·舒赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Contrafect Corp
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of CN112368376A publication Critical patent/CN112368376A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980036007.XA 2018-03-29 2019-03-29 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途 Pending CN112368376A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862650235P 2018-03-29 2018-03-29
US62/650235 2018-03-29
US201862721969P 2018-08-23 2018-08-23
US62/721969 2018-08-23
US201862722793P 2018-08-24 2018-08-24
US62/722793 2018-08-24
PCT/US2019/024912 WO2019191633A2 (en) 2018-03-29 2019-03-29 Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof

Publications (1)

Publication Number Publication Date
CN112368376A true CN112368376A (zh) 2021-02-12

Family

ID=68060804

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980036007.XA Pending CN112368376A (zh) 2018-03-29 2019-03-29 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途

Country Status (11)

Country Link
US (2) US11773140B2 (cg-RX-API-DMAC7.html)
EP (1) EP3775192A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021519083A (cg-RX-API-DMAC7.html)
KR (1) KR20200136980A (cg-RX-API-DMAC7.html)
CN (1) CN112368376A (cg-RX-API-DMAC7.html)
AU (1) AU2019245369A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020019484A2 (cg-RX-API-DMAC7.html)
CA (1) CA3095484A1 (cg-RX-API-DMAC7.html)
IL (1) IL277119B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020010075A (cg-RX-API-DMAC7.html)
WO (1) WO2019191633A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120924524A (zh) * 2025-10-14 2025-11-11 中国海洋大学 一种抗菌肽及其制备方法和在制备治疗肺炎的制剂中的应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016030580B1 (pt) * 2014-06-26 2023-12-19 The Rockefeller University Polipeptídeo de lisina e fragmento de polipeptídeo com atividade para matar bactérias gram-negativas
BR112020011433A2 (pt) 2017-12-12 2020-12-01 Contrafect Corporation identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa
US10988520B2 (en) * 2018-03-29 2021-04-27 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
WO2019191633A2 (en) 2018-03-29 2019-10-03 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
MX2020010071A (es) * 2018-03-29 2021-01-08 Contrafect Corp Polipeptidos anti-microbianos, derivados de bacteriofago, y sus usos contra bacterias gram negativas.
EP3840771A4 (en) * 2018-08-23 2023-04-19 Contrafect Corporation POLYPEPTIDE CONSTRUCTS WITH LYSINE ANTIMICROBIAL PEPTIDE (AMP), LYSINE, ISOLATED POLYNUCLEOTIDES ENCODING THEREOF AND USES THEREOF
MX2021012166A (es) * 2019-04-05 2021-11-03 Contrafect Corp Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano.
MX2021015563A (es) * 2019-07-05 2022-03-17 Contrafect Corp Polipéptidos anti-microbianos, derivados de bacteriófago, y sus usos contra bacterias gramnegativas y acidorresistentes.
JP2023502940A (ja) * 2019-11-14 2023-01-26 コントラフェクト コーポレイション 溶解素-抗微生物ペプチド(amp)ポリペプチドコンストラクト、溶解素、それをコードする単離ポリヌクレオチド及びその使用
WO2021211303A1 (en) * 2020-04-14 2021-10-21 Contrafect Corporation Antiviral, bacteriophage-derived polypeptides and their use against viruses
US20210324359A1 (en) * 2020-04-17 2021-10-21 Contrafect Corporation Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis
CA3213352A1 (en) * 2021-03-26 2022-09-29 Raymond Schuch Amurins, lysins, and lysin-antimicrobial peptide (amp) constructs active against gram-negative bacteria
WO2022236088A1 (en) * 2021-05-06 2022-11-10 Bioharmony Therapeutics Inc. Lysin polypeptide compositions and methods of use
FR3149209B1 (fr) * 2023-06-02 2026-04-03 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique
FR3149202B1 (fr) * 2023-06-02 2026-04-10 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et une huile.
WO2024246325A1 (en) * 2023-06-02 2024-12-05 L'oreal Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol
FR3149203B1 (fr) * 2023-06-02 2026-03-13 Oreal Composition anhydre comprenant une endolysine et de l’hydroxypropylmethylcellulose et/ou du pullulane
WO2024256710A2 (en) 2023-06-15 2024-12-19 Aurobac Therapeutics Sas Engineered lysin polypeptide constructs active against gram-negative bacteria
WO2025054593A2 (en) * 2023-09-07 2025-03-13 The Trustees Of The University Of Pennsylvania Molecular de-extinction of antibiotics enabled by deep learning

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482655A (zh) * 2009-06-26 2012-05-30 莱桑多公司 抗微生物剂
US20120189606A1 (en) * 2009-06-26 2012-07-26 Rob Lavigne Antimicrobial Agents
US20140120074A1 (en) * 2011-04-27 2014-05-01 Lysando Ag Antimicrobial agents
US20150140572A1 (en) * 2012-06-29 2015-05-21 Lysando Ag Composition for use in mycobacteria diagnosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2393224C2 (ru) 2004-11-12 2010-06-27 Новозимс Эдениум Байотек А/С Полипептиды с противомикробной активностью и кодирующие их полинуклеотиды
US20120135917A1 (en) 2009-06-16 2012-05-31 Eisaku Yoshihara Anti-Gram Negative Bacteria Agent
JP5847081B2 (ja) 2009-08-24 2016-01-20 カトリック ユニバーシテイト ルーベン ケイ.ユー. ルーベン アール アンド ディー エンドリシンOBPgpLYS
EP2468856A1 (en) 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
EP2699689A4 (en) 2011-04-21 2014-12-17 Univ Utrecht Holding Bv STREPTOCOCCUS BACTERIOPHAGEN LYSINE FOR THE TREATMENT OF GRAM-POSITIVE BACTERIA IN PETS AND UTILITIES
US9518252B2 (en) 2011-05-26 2016-12-13 Dsm Ip Assets B.V. Listeria bacteriophage P825 and uses thereof
US8790639B2 (en) 2012-03-28 2014-07-29 The United States Of America, As Represented By The Secretary Of Agriculture Enhanced antimicrobial lytic activity of a chimeric Ply187 endolysin
KR101391332B1 (ko) 2012-05-18 2014-05-07 연세대학교 산학협력단 카바페넴 제제에 내성을 보이는 아시네토박터 속의 균을 용균하는 박테리오파아지
CN102861324A (zh) * 2012-10-17 2013-01-09 重庆市第三人民医院 治疗耐碳青霉烯类鲍曼不动杆菌感染的生物试剂
BR112016030580B1 (pt) 2014-06-26 2023-12-19 The Rockefeller University Polipeptídeo de lisina e fragmento de polipeptídeo com atividade para matar bactérias gram-negativas
ES2934714T3 (es) 2015-09-17 2023-02-24 Contrafect Corp Polipéptidos de lisina activos contra bacterias Gram-negativas
KR102000120B1 (ko) 2017-01-26 2019-07-15 주식회사 코미팜 이유 자돈의 대장균증을 예방하기 위한 재조합 p22 라이소자임 - pmap36 융합 단백질을 이용한 장내독소형 대장균(etec) 고스트 백신 조성물
BR112020011433A2 (pt) 2017-12-12 2020-12-01 Contrafect Corporation identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa
WO2019191633A2 (en) 2018-03-29 2019-10-03 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
US10988520B2 (en) 2018-03-29 2021-04-27 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
MX2020010071A (es) 2018-03-29 2021-01-08 Contrafect Corp Polipeptidos anti-microbianos, derivados de bacteriofago, y sus usos contra bacterias gram negativas.
EP3840771A4 (en) * 2018-08-23 2023-04-19 Contrafect Corporation POLYPEPTIDE CONSTRUCTS WITH LYSINE ANTIMICROBIAL PEPTIDE (AMP), LYSINE, ISOLATED POLYNUCLEOTIDES ENCODING THEREOF AND USES THEREOF
US20210324359A1 (en) * 2020-04-17 2021-10-21 Contrafect Corporation Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482655A (zh) * 2009-06-26 2012-05-30 莱桑多公司 抗微生物剂
US20120189606A1 (en) * 2009-06-26 2012-07-26 Rob Lavigne Antimicrobial Agents
CN105440139A (zh) * 2009-06-26 2016-03-30 勒芬天主教大学,K.U.勒芬R&D 抗微生物剂
US20140120074A1 (en) * 2011-04-27 2014-05-01 Lysando Ag Antimicrobial agents
US20150140572A1 (en) * 2012-06-29 2015-05-21 Lysando Ag Composition for use in mycobacteria diagnosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NOBUAKI MORI 等: ""A peptide based on homologous sequences of the b-barrel assembly machinery component BamD potentiates antibiotic susceptibility of Pseudomonas aeruginosa"", 《J ANTIMICROB CHEMOTHER》, vol. 67, pages 2173 - 2181, XP055071268, DOI: 10.1093/jac/dks174 *
YINFENG LYU 等: ""Antimicrobial activity, improved cell selectivity and mode of action of short PMAP-36-derived peptides against bacteria and Candida"", 《SCIENTIFIC REPORTS》, vol. 6, pages 1 - 12 *
陈孙孝 等: ""颗粒溶素肽对白念珠菌的毒性作用"", 《第二军医大学学报》, vol. 27, no. 2, pages 140 - 142 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120924524A (zh) * 2025-10-14 2025-11-11 中国海洋大学 一种抗菌肽及其制备方法和在制备治疗肺炎的制剂中的应用

Also Published As

Publication number Publication date
KR20200136980A (ko) 2020-12-08
IL277119B1 (en) 2025-04-01
WO2019191633A3 (en) 2019-11-07
RU2020129467A (ru) 2022-05-04
EP3775192A4 (en) 2022-06-01
IL277119A (en) 2020-10-29
IL277119B2 (en) 2025-08-01
US11773140B2 (en) 2023-10-03
WO2019191633A2 (en) 2019-10-03
US20240018192A1 (en) 2024-01-18
BR112020019484A2 (pt) 2021-01-12
EP3775192A2 (en) 2021-02-17
JP2021519083A (ja) 2021-08-10
US20210047374A1 (en) 2021-02-18
MX2020010075A (es) 2021-01-08
AU2019245369A1 (en) 2020-10-29
CA3095484A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
US20240018192A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
CN108348574B (zh) 具有对抗革兰氏阴性菌的活性的溶素多肽
CN112292143A (zh) 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途
US20220402984A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
CN112368010A (zh) 抗微生物的、细菌噬菌体来源的多肽及其针对革兰氏阴性细菌的用途
CN114401735A (zh) 抗微生物的、细菌噬菌体来源的多肽及其针对革兰氏阴性和抗酸细菌的用途
WO2024256710A2 (en) Engineered lysin polypeptide constructs active against gram-negative bacteria
US20210324359A1 (en) Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis
KR20230162045A (ko) 그램-음성 박테리아에 대해 활성인 아무린, 리신, 및 리신-항미생물 펩타이드 (amp) 작제물
US20220411473A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
CN117377680A (zh) 针对革兰氏阴性细菌有活性的amurin溶素和溶素-抗微生物肽(AMP)构建体
CA3095473A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
RU2803121C2 (ru) Полипептидные конструкции лизин-противомикробный пептид (amp), лизины, выделенные полинуклеотиды, кодирующие их, а также варианты их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination